EyePoint, Inc. (EYPT) News
Track canonical SquawkNews coverage tagged to EYPT, EyePoint, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 22 indexed stories across 15 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
EYPT - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EYPT - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWS | Sep 16, 2026, 11:00 AM UTC
L
EYPT: Strong secondary endpoints and safety drive optimism ahead of the pivotal LUCIA trial
Recent phase III data showed strong safety and reduced treatment burden for wet AMD, despite missing the primary endpoint due to unusual control arm results. The upcoming LUCIA trial will address these findings, with com
NEWS | Sep 15, 2026, 12:26 PM UTC
L
EYPT: Strong secondary outcomes and safety drive optimism ahead of pivotal LUCIA trial and DME expansion
Recent phase III data showed strong secondary outcomes and safety, despite missing the primary endpoint due to unusual control arm results. The upcoming LUCIA trial, with improved analysis, is expected to be pivotal for
NEWS | Sep 15, 2026, 11:53 AM UTC
L
EYPT LUGANO trial reports strong secondary results and safety
EYPT said its LUGANO trial produced strong secondary outcomes showing reduced treatment burden and good safety. It also said the trial missed the primary endpoint due to an unusual control arm result.
EARNINGS | Sep 10, 2026, 03:10 PM UTC
L
EyePoint posts updated presentation on LUGANO Phase 3 topline results
The investor presentation highlights LUGANO Phase 3 DURAVYU topline results. It also says a wet AMD NDA filing is targeted for H1 2027.
EQUITY | Sep 10, 2026, 11:13 AM UTC
L
EYPT optimism rises as LUCIA trial secondary endpoints look strong
DURAVYU’s phase III LUGANO wet AMD trial missed its primary endpoint on randomization imbalance, but strong secondary endpoints, safety, and reduced injection burden support confidence for upcoming LUCIA results.
EQUITY | Sep 09, 2026, 01:28 PM UTC
L
TD Cowen cuts EyePoint to Hold, trims price target to $4
TD Cowen downgraded EyePoint to Hold from Buy and cut its price target to $4.00 per share from $20.00, according to Benzinga/TradingView News.
EQUITY | Sep 02, 2026, 01:31 PM UTC
L
EyePoint to participate in upcoming investor conferences, scientific meeting
EyePoint, Inc. (NASDAQ:EYPT) announced it will participate in upcoming investor conferences and a scientific meeting.
EQUITY | Sep 02, 2026, 11:07 AM UTC
L
EyePoint announces participation at upcoming investor conferences
EyePoint (EYPT) says it will participate in upcoming investor conferences and a scientific meeting.
EQUITY | Sep 02, 2026, 11:01 AM UTC
L
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm
EQUITY | Aug 28, 2026, 11:10 PM UTC
L
Downgrades hit AMRC, ANF, ATHM, EYPT, JBLU, KRG, METC, NCLH, TIGO
Several brokers lower or reiterate cautious ratings on AMRC, ANF, ATHM, EYPT, JBLU, KRG, METC, NCLH and TIGO, with no catalyst supplied in the feed.
EQUITY | Aug 18, 2026, 10:44 AM UTC
L
NY Empire State Manufacturing Index Rises to 20.6 in August
The New York Fed's Empire State Manufacturing Index surged to 20.6 in August from 15.6 in the prior month, topping market estimates of 11.
EARNINGS | Aug 17, 2026, 04:04 PM UTC
L
Empire State Manufacturing Index jumps to 20.6 in August
The New York Fed’s Empire State Manufacturing Index rises to 20.6 in August from 15.6 in the prior month, exceeding market estimates of 11, as U.S. stocks trade mixed.
EARNINGS | Aug 17, 2026, 01:39 PM UTC
M
EyePoint reports topline data from LUGANO Phase 3 DURAVYU 2.7mg trial
EyePoint (EYPT) announces topline data from LUGANO, the first of two pivotal Phase 3 trials for DURAVYU™ 2.7mg in wet AMD, with no additional figures provided.
EQUITY | Aug 17, 2026, 11:00 AM UTC
M
EyePoint grants inducement awards under Nasdaq Rule 5635(c)(4)
EyePoint Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) for EYPT.
REGULATION | Aug 14, 2026, 08:32 PM UTC
L
EYPT - EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EYPT - EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EARNINGS | Aug 05, 2026, 11:01 AM UTC
H
EyePoint Completes Enrollment
EyePoint completes phase 3 trials
EQUITY | Jul 30, 2026, 11:00 AM UTC
L
EYPT Eyepoint - enters settlement agreement with DOJ, oig-hhs, and dha on July 17, 2026 - SEC filing
EYPT Eyepoint - enters settlement agreement with DOJ, oig-hhs, and dha on July 17, 2026 - SEC filing
REGULATION | Jul 17, 2026, 08:07 PM UTC
L
EYPT U.S. Department of Justice - Eyepoint Pharmaceuticals to Pay $4.6M to Resolve False Claims Act Allegations
EYPT U.S. Department of Justice - Eyepoint Pharmaceuticals to Pay $4.6M to Resolve False Claims Act Allegations
EQUITY | Jul 17, 2026, 02:35 PM UTC
L
EYPT Initiated Buy and $40 PT @ Stifel
EYPT Initiated Buy and $40 PT @ Stifel
EQUITY | Jul 16, 2026, 11:10 AM UTC
L
EYPT Initiate with a Buy, $40 PT @ Stifel
EYPT Initiate with a Buy, $40 PT @ Stifel
EQUITY | Jul 15, 2026, 08:08 PM UTC
L
Chardan Capital Maintains Buy on EyePoint, Raises Price Target to $65
Chardan Capital analyst Andreas Argyrides maintains EyePoint (NASDAQ: EYPT ) with a Buy and raises the price target from $29 to $65.
EQUITY | Jul 01, 2026, 12:52 PM UTC